RECORDATI_RARE_DISEASES_INC.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$3.1M
Doctors Paid
5,038
Transactions
13,929
2024 Total
$2.2M
Payment Breakdown by Category
Research$1.8M (56.8%)
Consulting$293,160 (9.4%)
Food & Beverage$289,891 (9.3%)
Travel$56,555 (1.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.8M | 788 | 56.8% |
| Honoraria | $556,836 | 185 | 17.9% |
| Consulting Fee | $293,160 | 95 | 9.4% |
| Food and Beverage | $289,891 | 12,731 | 9.3% |
| Grant | $82,021 | 2 | 2.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $64,123 | 38 | 2.1% |
| Travel and Lodging | $56,555 | 86 | 1.8% |
| Gift | $3,120 | 3 | 0.1% |
| Education | $1,100 | 1 | 0.0% |
Payments by Type
Research
$1.8M
788 transactions
General
$1.3M
13,141 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| PAS576 | $382,273 | 10 | 77 |
| REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients | $182,081 | 0 | 128 |
| LCI699-RECAG-PASS-0572 | $155,900 | 15 | 453 |
| An Observational Study of Carbaglu for the Treatment of MMA and PA in Adults and Pediatrics | $154,372 | 0 | 20 |
| A Block-and-replace Therapy with Osilodrostat and Concomitant Glucocorticoid Replacement | $128,694 | 0 | 1 |
| Richard Auchus at Regents of the University of Michigan on A Block-and-replace Therapy with Osilodrostat and Concomitant Glucocorticoid Replacement | $128,694 | 1 | 1 |
| YUANQUAN Yang at Ohio State on A Phase 2 Study: Checkpoint Inhibitor Rechallenge in combination with Siltuximab for pts who had prior irAE | $106,145 | 1 | 1 |
| Eliza Geer at Memorial Sloan Kettering Cancer Center on Pasireotide treatment for prolactinoma patients who have failed dopamine agonist therapy | $100,625 | 1 | 1 |
| CLCI699C2203 | $50,537 | 1 | 22 |
| Detecting Mild Autonomous Cortisol Secretion in Patients with Adrenal Incidentaloma | $38,192 | 0 | 1 |
| Ricardo Correa at Cleveland Clinic on Detecting Mild Autonomous Cortisol Secretion in Patients with Adrenal Incidentaloma | $38,192 | 1 | 1 |
| Cytokine Release Syndrome in CAR-T Treatment | $37,500 | 0 | 1 |
| Mayur Narkhede at University of Alabama at Birmingham on Cytokine Release Syndrome in CAR-T Treatment | $37,500 | 1 | 1 |
| Non-interventional Study on Osilodrostat in Patients With Endogenous Cushings Syndrome (LINC6) | $34,262 | 0 | 68 |
| Mayur Narkhede at University of Alabama at Birmingham on Pharmacokinetic profile of siltuximab during ongoing CRS/ICANS in patients receiving CAR T-cell therapy | $30,000 | 1 | 1 |
| Pharmacokinetic profile of siltuximab during ongoing CRS/ICANS in patients receiving CAR T-cell therapy | $30,000 | 0 | 1 |
| Adriana Ioachimescu at The Medical College of Wisconsin on Brain Alterations in Patients with Cushings Disease: A Prospective Longitudinal Study | $25,111 | 1 | 2 |
| Donald Suh at The Regents of the University of California on Assessment and Improvement of Treatment for Corneal Involvement in Cystinosis | $25,000 | 1 | 1 |
| Incidence and Predictors of Severity of GWS after Curative Surgery in Patients with Endogenous CS | $25,000 | 0 | 1 |
| Irina Bancos at Mayo Clinic on Incidence and Predictors of Severity of GWS after Curative Surgery in Patients with Endogenous CS | $25,000 | 1 | 1 |
| Timothy Voorhees at Ohio State on Prevention of Cytokine Release Syndrome in CAR-T Treatment | $17,375 | 1 | 2 |
| Caimi Paolo at Cleveland Clinic on Pilot study of siltuximab CRS prophylaxis prior to treatment with epcoritamab, a CD3/CD20 bispecific antibody for treatment of B cell lymphomas | $8,965 | 1 | 1 |
| Pilot study of siltuximab CRS prophylaxis prior to treatment with epcoritamab, a CD3/CD20 bispecific antibody for treatment of B cell lymphomas | $8,965 | 0 | 1 |
| Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia (PASIPHY) | $1,871 | 1 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Richard Auchus, Md, MD | Endocrinology, Diabetes & Metabolism | Ann Arbor, MI | $142,228 | $0 |
| Yuanquan Yang, M.d, M.D | Medical Oncology | Columbus, OH | $106,145 | $0 |
| Eliza Geer, Md, MD | Endocrinology, Diabetes & Metabolism | New York, NY | $104,771 | $0 |
| Mary Elizabeth Patti, M.d, M.D | Endocrinology, Diabetes & Metabolism | Boston, MA | $82,468 | $0 |
| Dr. Nicholas Ah Mew, Md, MD | Clinical Genetics (M.D.) | Washington, DC | $80,000 | $0 |
| Dr. Mayur Narkhede, M.d, M.D | Hematology & Oncology | Birmingham, AL | $72,645 | $0 |
| Elena Christofides, Md, Face, MD, FACE | Endocrinology, Diabetes & Metabolism | Columbus, OH | $63,253 | $0 |
| Tracey Mclaughlin, Md, MD | Endocrinology, Diabetes & Metabolism | Stanford, CA | $61,947 | $0 |
| Dawn Davis, M.d., Ph.d, M.D., PH.D | Endocrinology, Diabetes & Metabolism | Madison, WI | $56,838 | $0 |
| Wenyu Huang, M.d., Ph.d, M.D., PH.D | Internal Medicine | Chicago, IL | $51,363 | $0 |
| Maria Fleseriu, Md, MD | Endocrinology, Diabetes & Metabolism | Portland, OR | $43,900 | $0 |
| Alison Gracom, Pa, PA | Medical | Irvine, CA | $42,108 | $0 |
| Marzieh Salehi, M.d, M.D | Internal Medicine | San Antonio, TX | $40,791 | $0 |
| Adriana Ioachimescu, Md, MD | Endocrinology, Diabetes & Metabolism | Milwaukee, WI | $39,042 | $0 |
| Sriram Machineni, Md, MD | Obesity Medicine | Chapel Hill, NC | $39,042 | $0 |
| Irina Bancos, M.d, M.D | Internal Medicine | Rochester, MN | $38,753 | $0 |
| Dr. Ricardo Correa Marquez, M.d, M.D | Endocrinology, Diabetes & Metabolism | East Providence, RI | $38,192 | $0 |
| Adrian Vella, M.d, M.D | General Practice | Rochester, MN | $38,188 | $0 |
| Dr. Beverly Biller, Md, MD | Internal Medicine | Boston, MA | $36,312 | $0 |
| Justin Ryder, M.d, M.D | Psychiatry | Aurora, CO | $35,424 | $0 |
| Dr. Melissa Toyos, Md, MD | Ophthalmology | Memphis, TN | $35,035 | $0 |
| Dr. Atil Kargi, M.d, M.D | Endocrinology, Diabetes & Metabolism | Chapel Hill, NC | $33,744 | $0 |
| Dr. Gordon Srkalovic, Md, MD | Hematology & Oncology | Lansing, MI | $31,205 | $0 |
| Dr. Kevin Yuen, Mbchb, Md, Frcp(Uk), MBCHB, MD, FRCP(UK) | Endocrinology, Diabetes & Metabolism | Phoenix, AZ | $28,195 | $0 |
| Donny Suh, Md, MD | Ophthalmology | Irvine, CA | $26,754 | $0 |
Ad
Top Products
- ISTURISA $844,163
- SYLVANT $468,001
Associated Products (9)
- ISTURISA $844,163
- SYLVANT $507,112
- PASIREOTIDE $382,273
- OSILODROSTAT $276,920
- CARBAGLU $233,904
- SIGNIFOR LAR $145,473
- PANHEMATIN $86,771
- Carbaglu $67,464
- CYSTADROPS $53,811
Payment Categories
- Food & Beverage $289,891
- Consulting $293,160
- Travel & Lodging $56,555
- Research $1.8M
About RECORDATI_RARE_DISEASES_INC.
RECORDATI_RARE_DISEASES_INC. has made $3.1M in payments to 5,038 healthcare providers, recorded across 13,929 transactions in the CMS Open Payments database. In 2024, the company paid $2.2M. The top product by payment volume is ISTURISA ($844,163).
Payments were distributed across 123 medical specialties. The top specialty by payment amount is Endocrinology, Diabetes & Metabolism ($984,965 to 1,164 doctors).
Payment categories include: Food & Beverage ($289,891), Consulting ($293,160), Research ($1.8M), Travel & Lodging ($56,555).
RECORDATI_RARE_DISEASES_INC. is associated with 9 products in the CMS Open Payments database, including ISTURISA, SYLVANT, and PASIREOTIDE.